guest ::
| Home > Publications database > Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. > print |
| Home > Publications database > Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. > print |
| 001 | 148865 | ||
| 005 | 20240229120020.0 | ||
| 024 | 7 | _ | |a 10.1158/2326-6066.CIR-18-0865 |2 doi |
| 024 | 7 | _ | |a pmid:31597643 |2 pmid |
| 024 | 7 | _ | |a 2326-6066 |2 ISSN |
| 024 | 7 | _ | |a 2326-6074 |2 ISSN |
| 024 | 7 | _ | |a altmetric:68226231 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2020-00057 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Di Tacchio, Mariangela |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. |
| 260 | _ | _ | |a Philadelphia, Pa. |c 2019 |b AACR |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1581687074_25937 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Glioblastoma (GBM) is a non-T-cell-inflamed cancer characterized by an immunosuppressive microenvironment that impedes dendritic cell maturation and T-cell cytotoxicity. Proangiogenic cytokines such as VEGF and angiopoietin-2 (Ang-2) have high expression in glioblastoma in a cell-specific manner and not only drive tumor angiogenesis and vascular permeability but also negatively regulate T-lymphocyte and innate immune cell responses. Consequently, the alleviation of immunosuppression might be a prerequisite for successful immune checkpoint therapy in GBM. We here combined antiangiogenic and immune checkpoint therapy and demonstrated improved therapeutic efficacy in syngeneic, orthotopic GBM models. We observed that blockade of VEGF, Ang-2, and programmed cell death protein-1 (PD-1) significantly extended survival compared with vascular targeting alone. In the GBM microenvironment, triple therapy increased the numbers of CTLs, which inversely correlated with myeloid-derived suppressor cells and regulatory T cells. Transcriptome analysis of GBM microvessels indicated a global vascular normalization that was highest after triple therapy. Our results propose a rationale to overcome tumor immunosuppression and the current limitations of VEGF monotherapy by integrating the synergistic effects of VEGF/Ang-2 and PD-1 blockade to reinforce antitumor immunity through a normalized vasculature. |
| 536 | _ | _ | |a 899 - ohne Topic (POF3-899) |0 G:(DE-HGF)POF3-899 |c POF3-899 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Macas, Jadranka |0 0000-0002-1661-2525 |b 1 |
| 700 | 1 | _ | |a Weissenberger, Jakob |b 2 |
| 700 | 1 | _ | |a Sommer, Kathleen |b 3 |
| 700 | 1 | _ | |a Bähr, Oliver |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Steinbach, Joachim P |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Senft, Christian |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Seifert, Volker |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Glas, Martin |0 P:(DE-He78)a44ef83e4213638f939d4e35a3c52d34 |b 8 |
| 700 | 1 | _ | |a Herrlinger, Ulrich |b 9 |
| 700 | 1 | _ | |a Krex, Dietmar |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Meinhardt, Matthias |b 11 |
| 700 | 1 | _ | |a Weyerbrock, Astrid |b 12 |
| 700 | 1 | _ | |a Timmer, Marco |b 13 |
| 700 | 1 | _ | |a Goldbrunner, Roland |b 14 |
| 700 | 1 | _ | |a Deckert, Martina |b 15 |
| 700 | 1 | _ | |a Scheel, Andreas H |b 16 |
| 700 | 1 | _ | |a Büttner, Reinhard |b 17 |
| 700 | 1 | _ | |a Grauer, Oliver M |b 18 |
| 700 | 1 | _ | |a Schittenhelm, Jens |0 0000-0002-9168-6209 |b 19 |
| 700 | 1 | _ | |a Tabatabai, Ghazaleh |0 P:(DE-HGF)0 |b 20 |
| 700 | 1 | _ | |a Harter, Patrick |0 P:(DE-He78)b15b56a6ed37417d476470c60c0140ff |b 21 |
| 700 | 1 | _ | |a Günther, Stefan |b 22 |
| 700 | 1 | _ | |a Devraj, Kavi |0 0000-0002-5005-3413 |b 23 |
| 700 | 1 | _ | |a Plate, Karl H |0 P:(DE-HGF)0 |b 24 |
| 700 | 1 | _ | |a Reiss, Yvonne |0 P:(DE-HGF)0 |b 25 |
| 773 | _ | _ | |a 10.1158/2326-6066.CIR-18-0865 |g Vol. 7, no. 12, p. 1910 - 1927 |0 PERI:(DE-600)2732517-9 |n 12 |p 1910 - 1927 |t Cancer immunology research |v 7 |y 2019 |x 2326-6074 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:148865 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)a44ef83e4213638f939d4e35a3c52d34 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 20 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 21 |6 P:(DE-He78)b15b56a6ed37417d476470c60c0140ff |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 24 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 25 |6 P:(DE-HGF)0 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF3-890 |0 G:(DE-HGF)POF3-899 |2 G:(DE-HGF)POF3-800 |v ohne Topic |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |
| 914 | 1 | _ | |y 2019 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CANCER IMMUNOL RES : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b CANCER IMMUNOL RES : 2017 |
| 920 | 1 | _ | |0 I:(DE-He78)L501-20160331 |k L501 |l DKTK Frankfurt |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)L401-20160331 |k L401 |l DKTK Essen |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)L301-20160331 |k L301 |l DKTK Dresden |x 2 |
| 920 | 1 | _ | |0 I:(DE-He78)L801-20160331 |k L801 |l DKTK Tübingen |x 3 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)L501-20160331 |
| 980 | _ | _ | |a I:(DE-He78)L401-20160331 |
| 980 | _ | _ | |a I:(DE-He78)L301-20160331 |
| 980 | _ | _ | |a I:(DE-He78)L801-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|